Bayer HealthCare Pharmaceuticals Signs Three-Year Renewal Agreement for MR Contrast Media

November 9, 2007 - Bayer HealthCare Pharmaceuticals announced that the company has been awarded a three-year contract renewal by HealthTrust Purchasing Group, LP (HealthTrust), to make Magnevist (gadopentetate dimeglumine) Injection available to members of the HealthTrust network.

Magnevist is used to enhance certain MRI procedures, and reportedly has the broadest range of FDA approved indications of any MRI contrast agent for adult and pediatric patients.

For the past seven years, Berlex, Inc. has provided the HealthTrust membership with MRI contrast media. Berlex is now part of Bayer HealthCare Pharmaceuticals as a result of Bayer's acquisition of Berlex's affiliate, Schering AG Germany. The new agreement calls for Bayer HealthCare Pharmaceuticals to continue as a provider of MRI contrast media to HealthTrust for the next three years.

For more information: www.pharma.bayer.com